The FDA permanently installed leadership across key drug and biologics review centers, following the administration’s nominations announced earlier this year. HHS named new permanent heads for CDER and CBER, while also filling the FDA’s director roles for biologics and tobacco products. Separately, the FDA also appointed Jared Seehafer as the agency’s first Deputy Commissioner for Technology and Artificial Intelligence, a role tied to the agency’s stated aim of using AI to accelerate review timelines. The leadership changes position the agency to set the near-term pace for regulatory modernization, particularly in review workflows and technology governance. The nominations and permanent appointments underscore a shift from “acting” leadership to stable management as a new FDA commissioner awaits confirmation. For sponsors, the move affects how quickly internal process changes can be implemented across CDER, CBER, and cross-cutting technology initiatives.